Breast Cancer Drug Raises Risk of Heart Problems in Older
WEDNESDAY, Aug. 10 (HealthDay News) -- The breast cancer drug
Herceptin increases the risk of heart problems in elderly patients,
especially those with a history of heart disease and/or diabetes, a
new study says.
Researchers analyzed the medical records of 45 women, ages 70 to
92, who were treated with Herceptin (trastuzumab) since 2005 and
found that 12 (26.7 percent) of them developed heart problems
caused by the drug.
That rate is slightly higher than what was noted in earlier
clinical trials of younger, healthier women.
In this new study, 33 percent of the women with a history of
heart disease developed either asymptomatic or symptomatic heart
problems as a result of taking Herceptin, compared with 9.1 percent
of women without a history of heart disease.
The researchers also found that about 33 percent of women with
diabetes developed heart problems, compared with 6 percent of
When the women with heart problems stopped taking Herceptin, all
but one recovered fully and five were able to re-start treatment
with the drug.
The study appears in the journal
Annals of Oncology.
"This is the first study specifically to assess trastuzumab-related cardiac toxicity and the cardiovascular factors that are associated with an increased risk in a selected population of elderly breast cancer patients," study author Dr. Cesar Serrano, who conducted the research while working as a clinical fellow at the Department of Medical Oncology Breast Cancer Centre at the Vall d'Hebron University Hospital in Barcelona, Spain, said in a journal news release.
"Trastuzumab is generally well-tolerated and, although there are some concerns about it causing heart problems, until now few risk factors have been identified among patients in clinical trials, most of whom are usually younger than 70 years and have good general health. Our study has demonstrated a significantly increased incidence of cardiac events among patients aged 70 and over with cardiovascular risk factors such as a history of cardiac disease and diabetes," said Serrano, who is now a postdoctoral research fellow at Brigham and Women's Hospital in Boston.
Serrano said the findings suggest that elderly women with one or
more heart risk factors who are being treated with trastuzumab
should be referred to a cardiologist. He also recommended closer
monitoring of such patients for possible heart problems.
The U.S. National Cancer Institute has more about
breast cancer treatment.
Copyright © 2011
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.